After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...